Nahum E, Lerman Y, Cohen D, Salpon R, Danon Y L
Childrens Medical Center of Israel, Petah Tikva.
Isr J Med Sci. 1994 Aug;30(8):600-3.
The purpose of this study was to evaluate the immunity of Israeli adults against the diphtheria toxin and to assess the immune response to a 2 Lf booster vaccination of diphtheria. The antibody levels against the toxin were measured in 200 volunteers aged 18-21. Later, a booster vaccination at a dosage of 2 Lf (flocculation units) was given and the immune response measured. We found that prior to the booster vaccination 174 (87%) of the study group had an antibody level > or = 0.1 IU/ml, 16 (8%) had an antibody level of > or = 0.06 IU/ml and < or = 0.09 IU/ml, and 10 (5%) had an antibody level of < or = 0.05 IU/ml. At the 10th day after the booster vaccination 185 (99%) acquired antibody level > or = 0.1 IU/ml, and at the 28th day all the vaccinees had antibody level above 0.1 IU/ml. When comparing the anamnestic and the delayed reaction to the booster vaccination, no significant difference was found between the group that prior to the vaccination had antibody level < or = 0.05 IU/ml and the group with antibody level > or = 0.06 IU/ml and < or = 0.09 IU/ml. Side effects were mainly local: 76 (38%) of the vaccinees had moderate local pain at the site of the injection and 40 (20%) had severe local pain. Abduction limitation of the injected arm was reported by 17 (8%) of the subjects. Weakness was reported by 67 (33%), headache by 18 (9%) and fever by 2 (1%) subjects. We conclude that antibody levels > or = 0.1 IU/ml are protective and booster vaccination at a dosage of 2 Lf raises the antibody levels to protective levels in all the vaccines.
本研究的目的是评估以色列成年人对白喉毒素的免疫力，并评估对白喉2Lf加强疫苗接种的免疫反应。在200名18 - 21岁的志愿者中测量了抗毒素抗体水平。随后，给予2Lf（絮状单位）剂量的加强疫苗接种并测量免疫反应。我们发现，在加强疫苗接种前，研究组中有174人（87%）的抗体水平≥0.1 IU/ml，16人（8%）的抗体水平≥0.06 IU/ml且≤0.09 IU/ml，10人（5%）的抗体水平≤0.05 IU/ml。在加强疫苗接种后的第10天，185人（99%）的抗体水平≥0.1 IU/ml，在第28天所有接种者的抗体水平均高于0.1 IU/ml。当比较加强疫苗接种的回忆反应和延迟反应时，接种前抗体水平≤0.05 IU/ml的组与抗体水平≥0.06 IU/ml且≤0.09 IU/ml的组之间未发现显著差异。副作用主要是局部的：76名（38%）接种者在注射部位有中度局部疼痛，40名（20%）有严重局部疼痛。17名（8%）受试者报告注射手臂外展受限。67名（33%）受试者报告有乏力，18名（9%）报告有头痛，2名（1%）报告有发热。我们得出结论，抗体水平≥0.1 IU/ml具有保护作用，2Lf剂量的加强疫苗接种可使所有接种者的抗体水平提高到保护水平。
